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Abstract: Background Several aetiologies account for exercise intolerance, with cardiac sarcoidosis (CS)
constituting a rare cause thereof. The pathogenesis of CS is still unresolved and its diagnosis still difficult
to establish, in the absence of any extracardiac manifestations in particular. Case summary A 49-year-
old amateur athlete presented with exercise intolerance during running over a 3-week period. Coronary
artery and structural lung disease were excluded by coronary angiography and computer tomography.
The symptoms could be reproduced during spiroergometry during which an exercise-induced high-degree
atrioventricular (AV) block was documented. During electrocardiographic monitoring, a 2:1 AV block was
observed. Different imaging modalities showed inferobasal septal inflammation and fibrosis. Transtho-
racic and transoesophageal echocardiography-guided endomyocardial biopsies were inconclusive and only
subsequent epicardial biopsy performed by transdiaphragmatic minimally invasive surgery lead to the
histological diagnosis of non-caseating granuloma, confirming CS. The patient was treated with high-
dose steroids 1 week after implantation of a primary prevention dual-chamber implantable cardioverter-
defibrillator (ICD). While tapering steroids, recurrence of myocardial inflammation occurred. However,
no tachytherapies and <0.1% right ventricular pacing were needed after 2 years of follow-up. Discussion
Differential diagnoses were either an infiltrative disease, a tumour, or an infectious disease. Due to the
different treatment options, we had to establish definite diagnosis by myocardial biopsy. Retrospectively,
the implantation of the ICD can be discussed. However, cardiac magnetic resonance imaging showed
fibrosis which is usually irreversible and substrate for potentially lethal ventricular arrhythmia. Confirm-
ing the diagnosis of isolated CS is challenging. Long-term management should be guided individually
based on clinical and imaging findings.
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Background Several aetiologies account for exercise intolerance, with cardiac sarcoidosis (CS) constituting a rare cause thereof.
The pathogenesis of CS is still unresolved and its diagnosis still difficult to establish, in the absence of any extracar-
diac manifestations in particular.
...................................................................................................................................................................................................
Case summary A 49-year-old amateur athlete presented with exercise intolerance during running over a 3-week period. Coronary
artery and structural lung disease were excluded by coronary angiography and computer tomography. The symp-
toms could be reproduced during spiroergometry during which an exercise-induced high-degree atrioventricular
(AV) block was documented. During electrocardiographic monitoring, a 2:1 AV block was observed. Different
imaging modalities showed inferobasal septal inflammation and fibrosis. Transthoracic and transoesophageal
echocardiography-guided endomyocardial biopsies were inconclusive and only subsequent epicardial biopsy
performed by transdiaphragmatic minimally invasive surgery lead to the histological diagnosis of non-caseating
granuloma, confirming CS. The patient was treated with high-dose steroids 1 week after implantation of a primary
prevention dual-chamber implantable cardioverter-defibrillator (ICD). While tapering steroids, recurrence of myo-
cardial inflammation occurred. However, no tachytherapies and <0.1% right ventricular pacing were needed after 2
years of follow-up.
...................................................................................................................................................................................................
Discussion Differential diagnoses were either an infiltrative disease, a tumour, or an infectious disease. Due to the different
treatment options, we had to establish definite diagnosis by myocardial biopsy. Retrospectively, the implantation of
the ICD can be discussed. However, cardiac magnetic resonance imaging showed fibrosis which is usually irrevers-
ible and substrate for potentially lethal ventricular arrhythmia. Confirming the diagnosis of isolated CS is challeng-
ing. Long-term management should be guided individually based on clinical and imaging findings.
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Exercise intolerance is a common symptom in sports cardiology with
a broad differential diagnosis, ranging from common coronary artery
disease to rare findings, e.g. cardiac sarcoidosis (CS) among several
other rare aetiologies. Pathogenesis of CS remains unresolved and
diagnosis often challenging, in the absence of extracardiac manifesta-
tions in particular.1 Up to 5% of patients with sarcoidosis present
with clinically manifest and another 20% of patients with asymptom-
atic, clinically silent cardiac involvement.2 The clinical features of CS,
especially advanced conduction system disease and/or heart failure
are dependent on the location, extent, and duration of the disease.3
Timeline
Case presentation
A 49-year-old amateur athlete presented with exercise intolerance
(by means exertional dyspnoea and dizziness) during running for
3weeks. The patient has not had a syncopal episode or family history
of sudden cardiac death (SCD). He did not take any prescription or
non-prescription drugs. The travel history revealed several trips to
Iran in the past years. His medical history revealed an inguinal bullous
and crusty cutaneous lesion of 4 cm 5 cm 3months prior to initial
presentation that had been treated by a physician in Italy during the
summer holidays with topical steroid application for a few days. No
recurrence occurred.
At initial presentation at our hospital, vital signs and clinical exam-
ination were unremarkable (heart rate at 61 b.p.m., blood pressure
Work-up
Days
0 Electrocardiogram (ECG), echocardiography, coronary angiography, chest
computer tomography scan, Holter-ECG
2 Cardiac magnetic resonance imaging: inferobasal mass
5 Spiroergometry: high-degree atrioventricular block
8 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET): focal sep-
tal inflammation, no extracardiac manifestations
14 Transthoracic echocardiography-guided endomyocardial biopsy (EMB)
21 Deep vein thrombosis! anticoagulation
22 Transoesophageal echocardiography-guided EMB
33 Transdiaphragmatic cardiac punch biopsy
41 Dual-chamber implantable cardioverter-defibrillator (ICD) implantation
Follow-up
Months after ICD implantation Steroid dose (mg) qd
0 Initiating steroids 0.8 mg/kg 60
1 Patient asymptomatic, steroid tapering over months 50
2 Stop anticoagulation 50
6 FDG-PET: no inflammation 35
10 FDG-PET: recurrence of inflammation 17.5! 40
13 Azathioprine 50 mg qd 20
15 Azathioprine stop (nausea) 17.5
20 FDG-PET: no inflammation 12.5
25 FDG-PET: mild inflammation 10! 20
26 Methotrexate 10 mg qwk 15
Learning points
• Spiroergometry is a useful tool for work-up of exercise intolerance.
• Diagnosis of isolated cardiac sarcoidosis is difficult. Cardiac biopsy is crucial for definite diagnosis in the absence of any extracardiac
manifestations.
• If endomyocardial biopsies remain unspecific, a surgical epicardial approach can be helpful—especially when pathology is involving more the
epicardial than endocardial layers.
• Cardiac sarcoidosis is associated with sudden cardiac death due to both brady- and tachyarrhythmias.
• Regular follow-up visits are needed for steroid-dose adjustment based on clinical and imaging findings.














122/77mmHg, temperature 36.5C, normal cardiac and pulmonary
examination). D-dimers and inflammation markers were negative
[leucocytes 4.89 g/L (normal 3–9.6 g/L), C-reactive protein 0.8mg/L
(normal <5mg/L)].
Resting 12-lead electrocardiogram showed an incomplete right
bundle branch block with atrioventricular (AV) block I (Figure 1A).
Rhythm monitoring showed intermittent 2:1 AV block. Performing a
spiroergometry, we were able to reproduce the symptoms while
Figure 1 (A) Initial resting 12-lead electrocardiogram. Incomplete right bundle branch block and atrioventricular block I. Calibration 10 mm/mV
and speed 25 mm/s. (B) 12-lead electrocardiogram. High-degree atrioventricular block during spiroergometry at 90 W. Calibration 10 mm/mV and
speed 25mm/s.




























documenting an exercise-induced high-degree AV block (Figure 1B).
Initial transthoracic echocardiography raised questionable wall mo-
tion abnormalities and in retrospect, a mass in the inferobasal septum
(Figure 2A). Left ventricular ejection fraction was normal. Subsequent
coronary angiography excluded coronary artery disease and com-
puter tomography of the chest did not reveal any structural pulmon-
ary disease. Cardiac magnetic resonance imaging (CMR) showed an
intracardiac mass involving the inferobasal septum describing a for-
mation of 5 cm 1 cm 1 cm. Late gadolinium enhancement (LGE)
was positive at this particular site (Figure 2B). However, no active per-
fusion of this particular site was seen in coronary angiography nor
CMR.
18F-fluorodeoxyglucose-positron emission tomography (FDG-
PET) documented an intense uptake of this mass, indicating an inflam-
matory process (Figure 2C).
Clinical examination, abdominal ultrasound, and whole-body
FDG-PET did not demonstrate any extracardiac focus or lesion. In
addition, inflammation markers were negative (sIL-2 receptor,
Figure 2 (A) Transthoracic echocardiography, short axis. Intracardiac mass located in the inferobasal septum. (B) Cardiac magnetic resonance
imaging, short axis. Late gadolinium enhancement in the inferobasal septum. (C) 18F-fluorodeoxyglucose-positron emission tomography. Intense up-
take in the inferobasal septal region. LV, left ventricle; PET, positron emission tomography; RV, right ventricle. *Intracardiac mass.































antinuclear antibodies, anti-neutrophil cytoplasmic antibodies),
serum calcium and angiotensin-converting enzyme were normal
[2.38mmol/L (normal 2.09–2.54mmol/L), 16.5U/L (normal 12–
68U/L)]. Microbiology did not reveal any abnormalities: blood cul-
tures for aerobic and anaerobic bacteria and mycobacteria were
negative. Brucella species, Bartonella henselae, Treponema pallidum,
Borrelia burgdorferi, and Coxiella burnetii antibodies as well as the result
of the HIV test were all negative. Travel history to Iran raised pre-test
probability for mycobacterial infection. However, polymerase chain
reaction for tuberculosis and blood cultures for mycobacteria
remained negative. Dermatologist-performed full-body skin examin-
ation revealed only unremarkable cutaneous lesions that were con-
sidered as non-specific and not typical for sarcoidosis.
So far, blood tests did not reveal any further abnormalities.
Due to lack of extracardiac manifestations, we attempted to con-
firm diagnosis by endomyocardial biopsy (EMB). Despite optimal
transthoracic and transoesophageal echocardiographic guiding
(Figure 3), however, all samples remained non-specific.
Moreover, a deep vein thrombosis (DVT) occurred despite ad-
equate thrombosis prophylaxis during hospitalization, underlining the
active (inflammatory) process. After initial anticoagulation with hep-
arin, edoxaban (60mg qd) was started for treatment of DVT.
Given its location in the inferobasal septum, and as the pathology
was involving more the epicardial than endocardial layer, we per-
formed an epicardial punch biopsy on the beating heart via a minimal-
ly invasive transdiaphragmatic approach thus avoiding open-heart
surgery.
Histological examination of this punch biopsy demonstrated non-
caseating granuloma (Figure 4), highly suggestive for CS.
In summary, after thorough exclusion of any extracardiac manifes-
tations, histological results confirmed criteria for an isolated CS.2
Due to ventricular tachyarrhythmias and/or AV conduction block,
SCD in CS is reported in up to 30–65%. Due to the presence of LGE
on CMR—implicating potential irreversible fibrosis—and intermit-
tent high-degree AV block, we felt that there was the need for a
dual-chamber device. Hence, we decided to insert a transvenous
dual-chamber implantable cardioverter-defibrillator (ICD) for
primary prevention of SCD and brady pacing. To facilitate wound
healing and reducing the risk of wound infection after ICD implant-
ation, we started high-dose steroids (prednisone 0.8mg/kg qd)
1week after implantation.
Figure 3 Transoesophageal echocardiography. Guiding of endomyocardial biopsy in two planes. RV, right ventricle. *Intracardiac mass.
Figure 4 Histological sample from the inferoseptal right ventricle
(haematoxylin and eosin stain). *Non-caseating granuloma.



































































































































After establishing steroids, PR-interval shortened from 224 to
150ms. Four weeks later, at the first follow-up visit, the patient was
already asymptomatic during exercise with 1:1 AV conduction during
effort. Steroids were tapered over time (10mg less every 1–
2months). To avoid or diminish side effects of long-term immuno-
suppression with steroids, pneumocystis pneumonia prophylaxis
with trimethoprim-sulfamethoxazole, gastric protection with panto-
prazole, and osteoporosis prophylaxis with calcium, vitamin D, and
alendronic acid were established. Due to recurrence of myocardial
inflammation (FDG-PET) after 10months, we increased the
steroid-dose and initiated additive immunosuppressive therapy with
azathioprine 3months later to diminish side effects of long-term
steroid intake. Because of nausea, this approach had to be aban-
doned. As there were no signs of recurrence of myocardial inflamma-
tion (FDG-PET) steroids were tapered again. After recurrence of
mild inflammation, methotrexate was initiated in a dose of 10mg per
week and subsequently increased.
During last follow-up, 2 years after ICD implantation, no tachy-
therapies and <0.1% right ventricular (RV) pacing by the ICD were
necessary.
Discussion
Differential diagnoses of the intracardiac inflammation process, docu-
mented by multi-modality imaging, were an infiltrative disease, a tu-
mour or an infectious disease (travel history to Iran and Italy).
Theoretically, the above-mentioned skin lesions could have been an
earlier, cutaneous manifestation of CS. Subsequent full-body skin
evaluations by a dermatologist in our clinic, however, did not detect
any signs of cutaneous sarcoidosis.
Malignant and infectious diseases could not be completely ruled
out, and histopathological evaluation is required for the definite
diagnosis of isolated CS.2,4 As the FDG-PET and CMR results
were suggestive of CS, an EMB was performed. While invasive
electroanatomical voltage mapping by electrophysiologists would
provide optimal guiding for an EMB, the inferobasal septal lesion
had been visible on echocardiography. Despite meticulous guiding
by echocardiography, the biopsy specimens obtained by EMB of
the right ventricle did not show any CS. Therefore, we proceeded
with an epicardial punch biopsy on the beating heart via a minim-
ally invasive transdiaphragmatic approach that finally confirmed the
diagnosis of CS. Indeed, histopathological evaluation demonstrated
that the sarcoid lesions involved more the epicardial than endo-
cardial layers. Of note, sensitivity of EMB in CS is reported to be
as low as 20%.5
In view of the paucity of data to guide clinical care in patients
with CS, current management recommendations in CS are still
largely based on expert opinion. In particular, whether patients
with advanced conduction system disease and preserved ventricu-
lar function should receive a bradypacemaker or an ICD is still
matter of debate.2,6 Results from observational studies, such as
the MIDFIN Study Group (Myocardial Inflammatory Diseases in
Finland)3 as well as by Nordenswan et al.7 add further support to
the recent AHA and HRS Expert Consensus Statement recom-
mendation supporting ICD implantation in CS patients with
advanced conduction system disease.
Importantly, clinical equipoise exists, as ICD complications have
been shown to be elevated in CS populations.7,8 This notwithstanding
we decided to implant a dual-chamber ICD for prevention of SCD
due to brady- or tachyarrhythmia2,9 as there was LGE observed on
CMR, which may reflect cardiac fibrosis. Recurrence of inflammation
raises probability of fibrotic remodelling. Usually, fibrosis is irrevers-
ible and implicates a substrate for potential fatal arrhythmia.
However, shared decision-making with the informed patient is of ut-
most importance.
Of note, after 2 years of follow-up, the patient did not need any
tachytherapies and RV pacing was <0.1%.
For optimal wound healing after ICD implantation, we waited with
steroid treatment for 1week. Currently, there exist no randomized
studies about detailed steroid use, i.e. starting dose, duration, taper-
ing, and other immunosuppressive regimen. Few studies of CS with
conduction abnormalities underline the effect of steroids.10,11 Based
on our local expertise, we decided to start steroids with 0.8mg/kg
(60mg qd) under the aspect of high-degree AV block and focal in-
flammation. Tapering of steroids and steroid-sparing agents should
be achieved over the first months and years of follow-up to diminish
side effects of long-term steroid intake. As the patient remained
asymptomatic, we tried to guide tapering with repetitive cardiac
FDG-PET imaging, which has to be weighed against potential long-
term radiation side effects.
In summary, imaging was already suggestive of CS. Confirmation of
the diagnosis of CS was subsequently obtained by cardiac biopsy. The
treatment regimen is based on two pillars: suppression of inflamma-
tion with steroids and prevention of SCD due to brady- and tachyar-
rhythmias with an ICD. Regular follow-up visits are of utmost
importance for adjustment of immunosuppression.
Conclusion
Isolated CS is a rare, but not irrelevant differential diagnosis of ex-
ercise intolerance, especially along with conduction abnormalities
during effort. Definite diagnosis is difficult to obtain but crucial for
adequate therapy. Management of follow-up remains difficult
due to individual disease progression and handling of
immunosuppression.
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Supplementary material is available at European Heart Journal - Case
Reports online.
Slide sets: A fully edited slide set detailing this case and suitable
for local presentation is available online as Supplementary data.
Consent: The author/s confirm that written consent for submis-
sion and publication of this case report including image(s) and associ-
ated text has been obtained from the patient in line with COPE
guidance.
Conflict of interest: Dr. BENUSSI reports personal fees from
ATRICURE, INC., outside the submitted work. FR reports grant sup-
port for the ESC-HFA Postgraduate Course in Heart Failure from
Novartis, Servier, Bayer, Abbott and Astra Zeneca and the
VASCEND trial from Novartis (all payments directly to the
University of Zurich). FR has been paid for the time spent as a com-
mittee member for clinical trials, advisory boards, other forms of con-
sulting and lectures or presentations. These payments were made
directly to the University of Zurich and no personal payments were
received in relation to these trials or other activities since January
2018. Before 2018 FR reports grants and personal fees from SJM /
Abbott, Servier, Novartis and Bayer, personal fees from Zoll, Astra
Zeneca, Sanofi, Amgen, BMS, Pfizer, Fresenius, Vifor, Roche,
Cardiorentis and Boehringer Ingelheim, other from Heartware and
grants from Mars, outside the submitted work. Dr. Saguner reports
educational grants from Abbott, Biosense Webster, Boston
Scientific, BMS-Pfizer, Bayer Healthcare, Biotronik, Medtronic and
holds shares from Gilead Sciences. Dr. Schindler reports personal
fees from Amgen, outside the submitted work. Dr. Steffel reports
personal fees from Amgen, personal fees from Astra Zeneca, grants
and personal fees from Bayer Healthcare, personal fees from
Boehringer-Ingelheim, grants and personal fees from Biosense
Webster, grants and personal fees from Boston Scientifc, personal
fees from Bristol-Myers Squibb, grants and personal fees from
Daiichi-Sankyo, grants and personal fees from Medtronic, personal
fees from Novartis, personal fees from Pfizer, personal fees from
Sanofi-Aventis, grants and personal fees from Abbott, personal fees
from Zoll, other from CorXL, grants and personal fees from
Biotronik, personal fees from Atricure, personal fees from Medscape,
personal fees from WebMD, personal fees from Merck / MSD, per-
sonal fees from Berlin Chemie / Menarini, outside the submitted
work. Dr. Steffel reports personal fees from Amgen, personal fees
from Astra Zeneca, grants and personal fees from Bayer Healthcare,
personal fees from Boehringer-Ingelheim, grants and personal fees
from Biosense Webster, grants and personal fees from Boston
Scientifc, personal fees from Bristol-Myers Squibb, grants and person-
al fees fromDaiichi-Sankyo, grants and personal fees fromMedtronic,
personal fees from Novartis, personal fees from Pfizer, personal fees
from Sanofi-Aventis, grants and personal fees from Abbott, other
from CorXL, grants and personal fees from Biotronik, personal fees
from Medscape, personal fees from WebMD, personal fees from
Merck / MSD, personal fees from Berlin Chemie / Menarini, outside
the submitted work. Dr. Zuber reports personal fees from Abbott,
Edwards Lifesciences, CorMedics, Cardiovalve and Pfizer outside the
submitted work
References
1. Okada DR, Bravo PE, Vita T, Agarwal V, Osborne MT, Taqueti VR, Skali H,
Chareonthaitawee P, Dorbala S, Stewart G, Di Carli M, Blankstein R. Isolated
cardiac sarcoidosis: a focused review of an under-recognized entity. J Nucl Cardiol
2018;25:1136–1146.
2. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson
MA, Kron J, Mehta D, Cosedis Nielsen J, Patel AR, Ohe T, Raatikainen P, Soejima
K. HRS expert consensus statement on the diagnosis and management of
arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:
1304–1323.
3. Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K,
Kaikkonen K, Tuohinen S, Haataja P, Kerola T, Kokkonen J, Pelkonen M,
Pietila-Effati P, Utrianen S, Kupari M. Cardiac sarcoidosis: epidemiology, char-
acteristics, and outcome over 25 years in a nationwide study. Circulation 2015;
131:624–632.
4. Kandolin R, Lehtonen J, Graner M, Schildt J, Salmenkivi K, Kivisto SM, Kupari M.
Diagnosing isolated cardiac sarcoidosis. J Intern Med 2011;270:461–468.
5. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diag-
nostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am
Heart J 1999;138:299–302.
6. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB,
Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC,
Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/
ACC/HRS guideline for management of patients with ventricular arrhythmias and
the prevention of sudden cardiac death: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines and the Heart Rhythm Society. Heart Rhythm 2018;15:e73–e189.
7. Nordenswan HK, Lehtonen J, Ekstrom K, Kandolin R, Simonen P, Mayranpaa M,
Vihinen T, Miettinen H, Kaikkonen K, Haataja P, Kerola T, Rissanen TT,
Kokkonen J, Alatalo A, Pietila-Effati P, Utriainen S, Kupari M. Outcome of cardiac
sarcoidosis presenting with high-grade atrioventricular block. Circ Arrhythm
Electrophysiol 2018;11:e006145.
8. Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, Rosenfeld L, Mitiku
TY, Cooper JM, Mehta D, Greenspon AJ, Ortman M, Delurgio DB, Valadri R,
Narasimhan C, Swapna N, Singh JP, Danik S, Markowitz SM, Almquist AK, Krahn
AD, Wolfe LG, Feinstein S, Ellenbogen KA. Efficacy and safety of implantable car-
diac defibrillators for treatment of ventricular arrhythmias in patients with car-
diac sarcoidosis. Europace 2013;15:347–354.
9. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm
J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck
K-H, Hernandez-Madrid A, Nikolaou N, Norekvål TM, Spaulding C, Van
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